Qalsody (Tofersen)

Tofersen is a medicine used to treat a type of ALS caused by a change in the SOD1 gene. It's given as a shot into the fluid around the spine. It works by lowering the amount of a harmful protein that the faulty gene makes.

Brand names:Qalsody
Medication

What people taking Qalsody (Tofersen) report

Every report comes from a Lived member, sent anonymously.

Have you tried Qalsody (Tofersen) for ALS?

NameHow it went

About Qalsody (Tofersen)

What It's For

Tofersen, sold as Qalsody, is a prescription treatment for amyotrophic lateral sclerosis (ALS) in adults whose ALS is linked to a change, or mutation, in the SOD1 gene, which carries the instructions for an enzyme called superoxide dismutase 1. ALS is a disease that damages the nerve cells controlling voluntary muscles, causing weakness that spreads over time and eventually affects speech, swallowing and breathing. Only about 2% of people with ALS have a SOD1 mutation, so tofersen is relevant only after genetic testing confirms one. It is not approved for other forms of ALS, for children, or for people who carry a SOD1 mutation but have no symptoms. Tofersen received accelerated approval from the US Food and Drug Administration (FDA) in 2023. That means the approval was based on a biomarker rather than on proof of clinical benefit: in its main trial, tofersen sharply lowered neurofilament light chain, a protein released into the blood when nerve cells are damaged. The trial's main measure of daily function did not show a statistically clear difference after 28 weeks, and continued approval depends on further studies confirming that the drug helps people live better or longer.

How It Works

In SOD1-related ALS, the faulty gene produces a harmful form of this enzyme. That protein is toxic to the motor nerve cells in the brain and spinal cord. Tofersen is an antisense oligonucleotide, a short, lab-made strand of genetic material designed to match the instructions (messenger RNA) the cell uses to build SOD1. When tofersen binds to those instructions, the cell breaks them down, so less SOD1 protein is made. Because tofersen does not easily cross from the bloodstream into the brain and spinal cord, it is injected directly into the fluid surrounding them. Lowering SOD1 is meant to slow ongoing nerve damage. It does not repair nerve cells that have already been lost, which is one reason earlier treatment is thought to matter.

Dosage & Administration

Tofersen is given as an injection into the spinal fluid through a lumbar puncture (also called a spinal tap), in which a needle is placed between the bones of the lower back. It is done by clinicians experienced with the procedure, usually at a specialist ALS or neurology center. A small amount of spinal fluid is removed first, and the dose is injected over one to three minutes. Some people receive sedation, or imaging to guide the needle, especially if their position or anatomy makes the procedure harder. Treatment starts with three loading doses given 14 days apart, followed by one dose every 28 days for as long as treatment continues. Every dose is the same amount. If a dose is missed, the team reschedules it as soon as possible and sets the next one from that date, so the regular visits are a significant ongoing commitment for the person and their caregivers.

Side Effects

The most common side effects in the main trial were pain (often in the back or limbs, partly related to the lumbar puncture), tiredness, joint pain and muscle aches. Headache after a lumbar puncture is common and usually lasts hours to a few days; a headache that persists for days and gets worse when sitting or standing should be reported, because it can mean spinal fluid is leaking. Routine spinal fluid tests often show raised white blood cells or protein, a sign of inflammation that usually causes no symptoms but is one reason for monitoring. Less often, tofersen has caused serious inflammation in the nervous system. These events resolved in the trials, and most people were able to continue treatment, but they need prompt attention. Contact the treating team right away for any of the following: new numbness, tingling, burning, or sharp shooting pain down the arms, legs or around the trunk, new bladder or bowel problems, or weakness that changes quickly in a way that seems different from the usual ALS course (possible inflammation of the spinal cord or nerve roots); a persistent or worsening headache with blurred or double vision or other changes in sight (possible raised pressure around the brain, which can swell the optic nerve); or fever, severe headache and a stiff neck (possible meningitis, an inflammation of the lining around the brain and spinal cord).

Interactions & Warnings

No drug interactions or contraindications are listed for tofersen. In its trial, people continued riluzole, a long-established ALS medicine taken by mouth, and edaravone (Radicava), an ALS treatment given by IV infusion or as an oral suspension. Tofersen is generally used alongside these and other supportive care, not instead of them. Anything that makes a lumbar puncture riskier, such as taking blood thinners, a bleeding disorder, a skin infection in the lower back or previous spine surgery, should be discussed with the team before each injection. There are no adequate human data on tofersen in pregnancy or breastfeeding, so anyone pregnant, planning pregnancy or breastfeeding should weigh this with their neurologist.

What to Expect

Tofersen is not expected to make ALS symptoms disappear, and early on most people notice no change. Blood levels of neurofilament light chain usually fall within months of starting, but slowing of the disease itself, when it happens, appears over a longer period. In long-term follow-up of the trial, people who started tofersen six months earlier tended to lose less function, strength and breathing capacity, and about a fifth to a quarter of early starters gained some strength or function over roughly three years, which is unusual in ALS. These results came from an open-label extension (everyone knew they were on the drug), the differences were not statistically certain, and the researchers were largely funded by the manufacturer, so how much benefit a given person can expect is still uncertain. Responses appear to vary with the specific SOD1 mutation and how early treatment begins. Treatment means a lumbar puncture every four weeks, regular neurological checks, and routine ALS care, including breathing, swallowing and nutrition assessments and therapy support. Decisions about continuing are made with the neurologist, weighing how the disease is progressing, how well the injections are tolerated and the person's own goals. Because the faulty gene is inherited, relatives may be offered genetic counseling.

Questions to Ask Your Doctor

  1. 1.Has genetic testing confirmed a SOD1 mutation, and what is known about how my specific mutation tends to progress?
  2. 2.What results are realistic for me, and how will we judge whether tofersen is helping?
  3. 3.Where will the injections be done, will I need sedation or imaging, and how do we handle missed or delayed doses?
  4. 4.Which symptoms after an injection should prompt a call to you, and how do I reach the team after hours?
  5. 5.Should my relatives consider genetic counseling or research studies for people who carry a SOD1 mutation?

Last reviewed • Oct 2026

Educational content, not medical advice.